We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisors Recommend GSK’s COPD Candidate Despite Safety Concerns
FDA Advisors Recommend GSK’s COPD Candidate Despite Safety Concerns
September 10, 2013
An FDA advisory panel overwhelmingly recommended approval of GlaxoSmithKline’s (GSK) chronic obstructive pulmonary disease (COPD) treatment Anoro Ellipta, but called for a postmarket study and labeling language to address lingering safety concerns.